Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Chimeric antigen receptor-T-cellebehandling

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Integration af specialiseret palliation og onkologi

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Formodet SARS-CoV-2-dødsfald hos en tidligere rask 50-årig mand

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Akut luftvejsobstruktion grundet uerkendt akalasi efter ukompliceret vaginal fødsel

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Dansk Kvalitetsdatabase for Nyfødte (DKN) -resumé af årsrapport 2018. Indikator 9: antibiotikabehandling

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Lokalanæstesitorakoskopi ved udredning af recidiverende pleuraeffusion

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Although treatment of haematological cancer has improved significantly during the latest decades, the prognosis is poor in case of relapse or refractory disease. This review describes the chimeric antigen receptor (CAR) T-cell therapy, which has emerged as a new promising treatment principle, in which the patient's own T-cells are genetically modified to recognise cancer cells. The possible side effects are usually only transient. A commercial CD19 CAR T-cell product has recently been approved as treatment for acute lympho-blastic leukaemia in children and young adults in Denmark, and a non-commercial CAR T-cell production is being established.

Original languageEnglish
JournalUgeskrift for Laeger
Volume181
Issue number20A
ISSN0041-5782
Publication statusPublished - 14 Oct 2019

ID: 58521171